Search Results
Studies of Complex Auditory Perception
This study involves testing auditory and speech perception using behavioral and non-invasive physiological measures in humans.
• Native English speaker as all test materials are in English
• Any neurological disorder diagnosis
Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma.
• between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)
• completed therapy and had with a complete response
• last date of prior systemic therapy was no more than one year ago
• must be English speaking
• have internet access through computer, tablet, or smartphone and an email address
• at least able to do limited selfcare, may be confined to bed or chair more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion criteria
A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma
This is an early study of a new drug, RGDCRAdCOX2F, as a single tumor injection in persons with adenocarcinoma of the pancreas. The main goal of the study is to find a safe dose of the study drug.
• documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes
• one prior line of therapy is permitted
• normal cardiac and pulmonary function
• participants with partners of childbearing potential must be willing to use at least two forms of effective birth control
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
• women who are pregnant or breastfeeding
• other types of pancreatic cancer
• history of human immunodeficiency virus (HIV) infection
• history of or active acute or chronic active hepatitis B or C infection
• taking 10mg/day or more of prednisone for more than one week
Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms
This study includes healthy adults between the ages of 21-70 who either use or do not cannabidiol (CBD) regularly. The purpose of this study is to learn about how CBD users and nonusers respond to stress. Participants must be willing to attend one in-person visit at the University of Minnesota Duluth campus
• 21 to 70 years old
• generally healthy
• use CBD regularly or do not use CBD
• willing to attend one in-person visit at the University of Minnesota Duluth campus
• current, unstable physical or mental health condition
• women who are currently pregnant
• current use of illicit substances (other than cannabis)
Neural Correlates of Pain and Alcohol Consumption in Chronic Temporomandibular Disorder (TMD)
The purpose of this research is to better understand how alcohol impacts pain processing in people with Temporomandibular Disorder (TMD) using MRI technology.
• 21 years of age or older
• report regular drinking
• have a diagnosis of a Temporomandibular Disorders
• diagnosis of Alcohol Use Disorder
Care Partners and Patients Navigating Year 1 of Dyadic Self-Management post-LVAD
The first year after LVAD implant involves a lot of changes to managing life with an LVAD for both the patient and the caregiver (informal or family care partner). Both patient and care partner will enroll in the study so that we can better understand the experiences of each person, including: self-management, emotional wellbeing, care partner experience and quality of life. You will be asked to fill out questionnaires after LVAD implant (at four time-points) over six months. We also ask you to wear a research watch (for ten days) to measure activity and rest. You can do this entire study from your home.
Hybrid Content Confirmation and Cognitive Debriefing Interviews of Patient-Reported Outcomes in Patients with Recurrent or Advanced Endometrial Cancer
This study collects data to better understand the experiences of women with recurrent or advanced endometrial cancer and if several questionnaires about recurrent or advanced endometrial cancer are relevant, clear, and understandable. Participants will get the same cancer therapy whether or not they take part in this study.
• confirmed diagnosis of recurrent or advanced endometrial cancer
• previously treated with platinum-based chemotherapy with or without anti-PD-(L)1 immunotherapy
• may not be able to do strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• able to read, write, and comfortably communicate in English
• willing and able to participate in a 90-minute interview via videoconference or telephone
S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
This trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning.
• diagnosis of estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer
• stage II or III breast cancer
• have not received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy
• must not be pregnant or breastfeeding
• see link to clinicaltrials.gov for complete inclusion criteria
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (COSMIC)
The objective of this study is to examine the association between cannabis and/or cannabinoid use and cancer-related symptoms assessed monthly for one year in adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer who are planning or recently started to receive one or more systemic cancer directed therapies with chemotherapy and/or immune check point inhibitors (ICIs) targeting PD-1, PD-L1 or CTLA-4. Participants complete surveys and have their medical records reviewed on study.
• newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer
• planned treatment with systemic chemotherapy and/or immune checkpoint inhibitor therapy
• able to comprehend English or Spanish
• have a working email address and be must be willing to complete surveys online
• see link to clinicaltrials.gov for complete inclusion criteria
• currently enrolled in an treatment trial to manage cancer symptoms
• women who are pregnant
COG ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.
• 21 or younger at time of enrollment
• newly diagnosed embryonal rhabdomyosarcoma (ERMS), spindle cell/sclerosing RMS, or FOXO1 fusion negative alveolar rhabdomyosarcoma
• must be enrolled in APEC14B1 (NCT02402244) prior to enrollment and treatment on ARST2032 (this trial)
• contact study team for more detailed criteria
• received prior chemotherapy and/or radiation therapy for cancer prior to enrollment
• unable to undergo radiation therapy
• Females who are pregnant
Causal inference and impact of prior beliefs on perception
The study is being conducted in order to further understand how we perceive the world, and if and how this may be different in individuals on the autism spectrum. We hope to further understand sensory processing differences in autism.
• 14to 36 years old
• right-handed
• normal (or corrected) vision - normal hearing
• able to sit quietly and make judgments of sensory stimuli
• diagnosis of Autism
• history of epilepsy
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2)
This is study to determine if a new drug, camizestrant, improves outcomes compared to usual adjuvant endocrine therapy for people who have ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence. People who have completed initial therapy (with or without chemotherapy) are eligible for the trial. Treatment is planned to continue for 7 years.
• 18 years to 130 years old
• confirmed ER+/HER2- early-stage resected invasive breast cancer
• may have received up to 12 weeks of endocrine therapy
• start the study within 12 months of definitive breast surgery
• strenuous activity may be restricted but able to walk and do light or sedentary work e.g., light house work, office work
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
• inoperable locally advanced or metastatic breast cancer
• history of any other cancer in the past 5 years that required treatment
• women who are pregnant or breast feeding
MT2019-38: Development and Psychometric Testing of a Pediatric Chronic Graft-Versus-Host Disease (GVHD) Symptom Scale (PCSS)
The purpose of this study is to develop a questionnaire specifically designed for children and adolescents, which will help health care providers to better measure how bothersome symptoms of cGVHD are for children and adolescents living with cGVHD. Another purpose of this study is to design a caregiver companion questionnaire, to allow caregivers to measure how bothersome the symptoms of cGVHD are for their child/adolescent.
• children aged 5 to 17 years old, who have undergone prior allogeneic stem cell transplant
• clinical diagnosis of Graft vs Host Disease (cGVHD)
• currently receiving systemic treatment for cGVHD (including phototherapies), or has had systemic therapy for cGVHD tapered to discontinuation within the past 12 months -eligible caregiver proxy who is willing to participate in the study
• see link to clinicaltrials.gov for complete inclusion criteria
• participant's cognitive ability would compromise their ability to participate in study related procedures
• see link to clinicaltrials.gov for complete exclusion criteria
Addition of a pectoserratus block to interscalene block in patients undergoing total shoulder replacement.
This research is being done to determine if pectoserratus block with bupivacaine will provide improvement in pain control and decrease opioid use, relative to pectoserratus block with a saline solution, among patients undergoing total shoulder arthroplasty.
• 18 years to 85 years old
• having a total shoulder arthroplasty or reverse total shoulder arthroplasty
• unable to receive regional anesthesia or nerve block
• Non-English speakers
• women who are pregnant
• currently using opioids and people who have chronic pain
Autonomic and Vascular Mechanisms of Cardiovascular Risk in Women with Post-traumatic Stress-Disorder (PTSD)
Having PTSD is associated with a higher risk of developing Cardiovascular Disease (CVD), which presents a major health risk for women, who are twice as likely as men to develop PTSD. The purpose of this study is to learn more about the mechanisms behind the relationship between PTSD and increased cardiovascular risk. Ultimately, our goal is to use the knowledge gained from this research study to help develop intervention and treatment strategies to protect the cardiovascular health of women with PTSD.
• female
• 18 years and older
• pre-menopausal
• must have experienced a past trauma, with or without PTSD Diagnosis
• pregnant or breastfeeding
• severe traumatic brain injury
• hypertension
• diabetes
• heart disease
• vascular disease
• illicit drug use within the past 6-months prior to participation
• inability or unwillingness to abstain from nicotine use for at least 12 hours prior to Study Visits 2 & 3
Effects of Pain on Laboratory Drinking Topography and Daily Drinking in People with Chronic Temporomandibular Disorder (TMD) Pain (TMD)
This study is about the impacts of pain, temporomandibular disorders (TMD), on individual drinking patterns.
• 21+ years of age, with a valid ID
• Fluent in English
• At least 1 drink 3 days/week over the past six months
• Diagnosis of TMD, myalgia, TMJ, or a combination
• Have a smartphone with Internet
• History of any psychotic disorder, current major depression, substance use disorder or current alcohol use disorder
• Serious medical illness
• Under-controlled hypertension or diabetes or neurological disease
• Impaired cognitive function
• Women who are pregnant breastfeeding, or intending to become pregnant
• Loss of sensation in lower legs or physical inability to complete study tasks
• Positive drug screening
• Medications that contraindicate alcohol use
• Comparison group: Chronic pain & TMD
MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank
The purpose of this research to enhance our understanding of adrenoleukodystrophy ALD and study biospecimens such assaliva, blood, urine and stool to identify potential biomarkers for early identification of dise. We invite people who have or are at risk to have ALD, including females who are known or at risk carriers of the mutation for ALD, to help us learn more.
• age 0 to 100
• patient or family member diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation
• patient or family member with known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene
• living in the United States and territories
• have undergone BMT or other cellular therapy
• not fluent in English who are unable to consent in-person
• people who are unable to read or write
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON). (TRITON)
In this trial, researchers want to learn more about how well durvalumab plus tremelimumab with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause the cancer to be less responsive to treatment. This trial is planned to have 280 participants. These participants will be randomly (by chance) divided into one of two groups. One group will receive durvalumab plus tremelimumab with standard of care chemotherapy and one group will receive pembrolizumab with standard of care chemotherapy.
• diagnosis of Stage IV non-squamous NSCLC not amenable to curative surgery or radiation
• tumors with STK11 or KEAP1 or KRAS mutations
• no prior chemotherapy or immunotherapy for metastatic cancer
• unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work
• men and women of child bearing age and their partners must use an acceptable method of contraception
• body weight of > 30 kg (66 pounds)
• see link to clinicaltrials.gov for complete Inclusion criteria
• evidence of acute or uncontrolled diseases or history of allogeneic organ transplant
• active or prior autoimmune or inflammatory disorders
• women who are pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant
• see link to clinicaltrials.gov for complete Exclusion criteria
Gender Identity Measurement In Early School Aged Children
The goal of this study is to learn more about how children (ages 5-8 years) describe their gender identities. We are also interested in learning more about the ways children think and develop. We will be giving children several tasks designed as games to assess flexibility in thinking, creativity, and the ability to take another person’s perspective.
• Ages 5 to 8
• English speaking
• unable to speak English
Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults (The Exergames Telerehabilitation Study)
The purpose of this study is to test the effects of an in person or home-based exergame intervention on improving cognition and fitness in community-dwelling older adults with memory complaints. The exergame refers to a new low-cost virtual reality cognitive game with cycling. We expect that participants will be in this research study for 4 months. Intervention sessions will require approximately 1 hour, 3 days per week for 3 months.
• at least 65 years old
• experiencing a memory or cognitive problem
• speak English
• no physical problems that prevent exercise
• diagnosis of dementia or mild cognitive impairment
• neurological or major psychiatric disorder, alcohol/chemical dependency or recent medical condition (anesthesia or COVID-19 brain fog) likely causing cognitive impairment
• currently enrolled in another clinical study
Listening effort in people with hearing impairment
The purpose of this research is to understand the effort needed to understand speech if hearing is impaired. Listening effort is higher in people with hearing impairment and has wide-ranging negative consequences across many aspects of a person’s life. The goal of this project is to explore factors that make listening effortful, with special focus on the need to repair perceptual mistakes by relying on context.
• adults with one or two cochlear implants
• non native English speakers
Dynamic Effects in Peripheral Auditory Processing
The purpose of this study is to learn more about the origin of tinnitus (phantom sound) and how age and hearing loss affect the ability to hear simple and complex sounds, such as tones and speech, presented in isolation and in the presence of other competing sounds. Possible participants may have normal hearing or mild-to-moderate hearing loss. Participants will be seated in a sound-treated room and listen to sounds over headphones, insert earphones (earbuds), or via loudspeakers. The tasks involve making judgments about the sounds, such as discriminating which of two sounds appeared to fluctuate in intensity or reporting the words in a sentence.
• Ages 18-30 yrs or 55-75 yrs
• Good overall health
• No hearing loss or mild to moderate hearing loss
• Neurologic disorders
• Past head trauma
• Tinnitus
Normalizing Cervical Intersegmental Kinematics with Spinal Manipulative Therapy - JIT
This study looks at how the neck moves in people with chronic neck pain and whether improving that movement can help guide better treatment. Researchers want to understand if unusual or limited spine movement can be used as a measurable sign of neck problems, and how those patterns change with different treatments.
• age 18-39
• Ongoing neck pain (lasting more than 12 weeks) that is not caused by a serious condition and is considered mild to moderate
• Neck pain rated higher than a 3 on a scale from 0 (no pain) to 10 (worst possible pain)
• received Botox injections for neck pain in the past 3 months that helped relieve symptoms
• regular use of opioid (narcotic) pain medications
• received neck manipulation or mobilization (like chiropractic treatment) in the past 6 months
• currently receiving other non-medication treatments for neck pain (such as physical therapy, massage, etc.)
• history of neck (cervical spine) surgery
• currently pregnant, trying to become pregnant, or breastfeeding
Global Patient Registry of Inherited Retinal Diseases
The purpose of this research study is to collect timely and relevant data that will support the evolving research needs of the Inherited Retinal Disease community (IRD), in order to provide insights that can be used to improve patient management, and to inform development of future treatments. No visits, assessments, or procedures are mandated, and follow-up will be captured as part of your standard of care. The planned length of registry is of 8 years with a potential to extend the duration as needs evolve.
• at least 3 years old
• documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) with any signs or symptoms of disease
• Caregiver participants must be at least 18 years old and identified by the participant as the primary care giver
• received a treatment in an Inherited Retinal Disease (IRD) related interventional trial, or is being screened for an IIRD-related interventional trial
• Caregiver participant has an IRD and has visual impairment
Comparison of motor and sensory thresholds for sacral neuromodulation
Participants in this research study are people who are considering or already receiving therapy using sacral nerve modulation (a treatment that sends electrical impulses to nerves in the lower back). In this research we are measuring brief responses to stimulation that is delivered using this therapy. With our research we are hoping to improve the therapy in the future. We expect that people would be in this research study for only a 20 minutes.
• has an implanted sacral neuromodulation device for control of urinary or pelvic symptoms, or plans to have one implanted
• has the ability provide signal (verbal or otherwise) regarding sensory or motor responses to stimulation delivery
• geographically available and is willing to come to the University for follow up visits and testing
• women who are pregnant
• diagnosis of a bleeding disorder or coagulopathies
• any abnormality of the urinary tract including the bladder, ureters or kidneys
• has had any invasive or surgical intervention involving the kidneys, bladder, urethra, rectum or vaginal wall within the last 6 months
Bladder Management Patient Reported Outcomes for Young Adults with Spina Bifida
The purpose of this study is to determine how different bladder management methods affect the quality of life for young people with spina bifida. We hope to find out if certain bladder management methods are associated with a better quality of life. This information could help doctors make better treatment decisions and counsel young people living with spina bifida.
• at least 14 years old
• diagnosis of spina bifida
• able to effectively communicate in English
• reconstructive surgery or urinary diversion in the last 3 months
• admitted to the hospital admission in the last month
MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
The primary purpose of this study is to gain information, especially disease free outcomes, using the tandem approach as compared to the historical information of using a single transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery and how patients are doing at 3 months and 1 year after the treatment. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.
• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Neural Correlates of Goal Prioritization and Conscientiousness
This research will use neuroimaging to study the brain systems involved in prioritizing goals effectively, as well as testing whether variation in those systems is associated with the personality trait conscientiousness, which reflects organization, self-discipline, and industriousness and predicts important health and other life outcomes.
• age 20 - 50
• right handed
• no major psychiatric illness
• claustrophobia
• any metal or devices in the body (e.g., pace makers, aneurysm clips etc.)
Senolytics To slOw Progression of Sepsis
Researchers hope that using Fisetin, an antioxidant, will reduce inflammation in the body caused by sepsis, which could help your body and organs have more time to recover. Placebo in this study will be something that looks similar to the study treatment, but does not contain any active drug. Everyone will receive 4 pills, but your group will determine how many of the pills are Fisetin. Researchers will look at the potential effects Fisetin or placebo has on inflammation in the body and how sick participants are at 7 days and 28 days.
• Age 65 or older
• Primary diagnosis of acute infection
• Expected length of hospital stay at least 48 hours
• No acute infection
• Known hypersensitivity or allergy to Fisetin
• Not admitted to hospital
• Enrolled in another Sepsis clinical trial
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1. We will also examine if there is a change in these blood and brain chemicals after participants begin taking oral N-acetylcysteine (NAC), which is available both as a prescription medication and a natural product that has antioxidant and anti-inflammatory effects.
• 18 years or older
• diagnosis of Type 1 Gaucher's Disease (GD1) who are medically stable
• on a stable medication therapy for 2 years, or if dosage or drug has been changed it has been at least 6 months and condition is stable
• women who are pregnant or breast feeding
• asthma that is currently being treated
• unable to have a MRI scan